Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances.

Autor: Bajpai SK; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Cambron-Mellott MJ; Kantar Health, New York, NY, USA., Peck E; Kantar Health, New York, NY, USA., Poon JL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Wang Q; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Mitchell BD; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Babrowicz J; Kantar Health, New York, NY, USA., Child CJ; Lilly Diabetes, Surrey, United Kingdom., Raibulet NK; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Beusterien K; Kantar Health, New York, NY, USA. Electronic address: Kathleen.beusterien@kantarhealth.com.
Jazyk: angličtina
Zdroj: Clinical therapeutics [Clin Ther] 2019 Oct; Vol. 41 (10), pp. 2073-2089.e6. Date of Electronic Publication: 2019 Sep 13.
DOI: 10.1016/j.clinthera.2019.08.006
Abstrakt: Purpose: People with diabetes taking insulin are at risk of severe hypoglycemia, an unpredictable, life-threatening event that requires assistance from others. Outside the clinical setting, glucagon is indicated for the treatment of hypoglycemia. However, there is significant unmet medical need to improve successful administration of glucagon by caregivers and acquaintances. This study assesses perceptions about glucagon delivery and potential effects of 2 glucagon delivery devices for severe hypoglycemia.
Methods: Qualitative interviews were conducted with people with diabetes (patients), caregivers, and acquaintances from a general population panel composed of individuals across the United States who have agreed to be recruited for research studies. Participants were recruited via email with a link to an online screener to determine eligibility. Experienced qualitative researchers conducted telephone interviews after a semistructured discussion guide, developed by the authors, that focused on aspirational device features and perceptions about the 2 devices: nasal glucagon and autoinjector glucagon; visuals of the instructions for use were displayed. Verbatim transcripts were developed, and a qualitative analysis software program, MaxQDA, was used to code responses and themes that emerged from the data.
Findings: A total of 45 (15 patients, 15 caregivers, and 15 acquaintances) interviews were conducted (mean ages, 55, 40, and 51, respectively). The most frequently spontaneously identified aspirational features for a new glucagon device were ease of use (29 [64%]), including being uncomplicated, premixed/ready to use, and ability to use quickly; small/easy to carry (9 [20%]); needle-free/no long needles (8 [18%]); and easy instructions (4 [9%]). In general, participants indicated that having a glucagon delivery device on hand would make them feel prepared, protected, and confident that others could assist in the event of severe hypoglycemia. More participants across all subgroups preferred nasal glucagon versus autoinjector glucagon (33 [73%] vs 12 [27%]). Favorable comments about nasal glucagon included that it appeared to be easy to carry, easy to use, and lacked a needle, that one does not need to remove clothing to use it, and that others likely would be more comfortable using it. Favorable comments about autoinjector glucagon included that it was familiar as a rescue device and that patients felt confident that the full dose would be delivered with it. There may be more hesitation using autoinjector glucagon versus nasal glucagon because of anxiety about needles and locating an injection site. Participants indicated that they would feel more comfortable socially using nasal glucagon because it was viewed as more discreet and less embarrassing than using autoinjector glucagon; it was also considered less traumatic for use in children.
Implications: This research suggests that patients with diabetes, caregivers, and acquaintances prefer a device that is simple, compact, and ready to use. Nasal glucagon was generally preferred over autoinjector glucagon primarily because it lacks a needle and it appears to be less complicated.
(Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: